Abstract: Disclosed herein are levodopa prodrug compounds and methods for their use. Further disclosed herein are liquid pharmaceutical formulations comprising a levodopa-tyrosine conjugate and a stabilizer, wherein the liquid pharmaceutical formulations may further comprise a decarboxylase inhibitor, such as carbidopa, an antioxidant, a solvent, or any other pharmaceutically acceptable excipient. Further disclosed are methods of treating generative conditions and/or conditions characterized by reduced levels of dopamine in the brain, such as Parkinson's disease, comprising administering the disclosed prodrugs and/or liquid pharmaceutical formulations.

Abstract: The present invention discloses various aqueous pharmaceutical compositions comprising a levodopa amide compound, or a salt thereof, which are stable for at least 24 hours at room temperature, and use thereof in treatment of diseases or disorders characterized by neurodegeneration and/or reduced levels of brain dopamine, e.g., Parkinson's disease.